The temporary spending bill that the House and Senate approved last night will keep the federal government operating through ...

Some muscles are resistant to the loss of motor neurons seen in patients with spinal muscular atrophy, and new research has ...

If approved, Molbreevi could be the first FDA-approved treatment for patients with autoimmune pulmonary alveolar proteinosis, ...

Now at the highest percentage in over a decade, this number has rebounded from 42% in 2013 during the rollout of the ...

Although the primary endpoint was not met in a phase 2 study of women who used CBD before a scan, researchers say CBD does ...

Tryngolza is once-monthly, subcutaneous RNA-targeted therapy and is expected to be available by the end of the year with a ...

The new, now-defeated bill eliminated the PBM reform measures included in a larger spending bill that the president-elect and ...

The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The boxed warning follows a safety warning the FDA issued in September about the risk of liver injury from the use of Veozah ...

Women are more than twice as likely to develop post-traumatic stress disorder than men, and a new study demonstrates for the ...

In past trials, ketamine intravenous treatment has shown promise, with 64% of depression patients in trials experiencing ...